Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Gastric String Test Combined With a Rapid Antigen Assay for Helicobacter Pylori Detection

1 november 2026 bijgewerkt door: Fu Jen Catholic University Hospital

A Pilot Study Evaluating a Novel Minimally Invasive String-test and Rapid Antigen Assay for Helicobacter Pylori Detection

This single-center, open-label, prospective pilot study aims to evaluate the feasibility, safety, and preliminary diagnostic performance of a minimally invasive gastric string sampling device combined with a rapid antigen assay for the detection of Helicobacter pylori infection.

A total of 40 participants with documented ^13C-urea breath test (UBT) results will be enrolled, including 30 UBT-positive and 10 UBT-negative participants. All participants will undergo gastric mucus collection using a disposable string sampling device, followed by H. pylori rapid antigen testing.

The primary objective is to assess the diagnostic sensitivity and specificity of the investigational test using ^13C-UBT as the reference standard. The secondary objective is to explore the correlation between the semi-quantitative test-line (T-line) color intensity of the rapid antigen assay and the corresponding UBT delta-over-baseline (DOB) values.

Studie Overzicht

Toestand

Nog niet aan het werven

Gedetailleerde beschrijving

Background and Rationale

Helicobacter pylori infection is a major cause of chronic gastritis, peptic ulcer disease, and gastric cancer. Commonly used non-invasive diagnostic methods include the ^13C-urea breath test (UBT) and stool antigen testing. Although these methods are widely used, stool-based testing requires specimen collection and handling, while UBT generally requires specialized analytical equipment.

A minimally invasive gastric string sampling device may provide an alternative approach for obtaining gastric specimens without conventional upper gastrointestinal endoscopy. Combining this sampling method with a rapid antigen assay may offer a convenient approach for H. pylori detection. However, the diagnostic performance of this combination using string-collected gastric mucus has not yet been established.

Study Design

This is a single-center, prospective, single-group pilot diagnostic accuracy study conducted at Fu Jen Catholic University Hospital, Taiwan.

An enriched enrollment strategy will be adopted to include 30 participants with positive UBT results and 10 participants with negative UBT results. All participants will undergo the same investigational procedure, and their previously obtained ^13C-UBT results will serve as the reference standard for diagnostic comparison.

Investigational Procedure

The investigational procedure combines two medical devices:

  1. Disposable Gastric Specimen Collection String: A minimally invasive gastric sampling device distributed by POCT Biotech Co., Ltd. (CE-certified, CE No. 6976663940137), used to collect gastric mucus specimens.
  2. Helicobacter pylori Rapid Antigen Test: A rapid antigen assay manufactured by Strong Biotech Co., Ltd. (Taiwan Food and Drug Administration Medical Device License No. 007277), used to detect H. pylori antigens in the collected specimens.

The use of string-collected gastric mucus with this rapid antigen assay represents an investigational application. Results obtained from this procedure will be used exclusively for research purposes and will not guide clinical diagnosis or treatment decisions.

Study Procedures

Participants will fast overnight before the study procedure. Each participant will swallow a disposable gastric specimen collection capsule with approximately 250 mL of water. After the capsule dissolves, the attached string will remain in the stomach for approximately 60 minutes to absorb gastric mucus.

The string will subsequently be retrieved by trained study personnel and immersed in the designated antigen extraction buffer. The extracted specimen will then be applied to the H. pylori rapid antigen test cassette, and the result will be interpreted after approximately 3-5 minutes.

In addition to qualitative interpretation, two independent investigators blinded to the participants' UBT results will assess the test-line (T-line) color intensity using a standardized reference chart, assigning a semi-quantitative score ranging from 0 to 4.

Safety Monitoring

Participant discomfort during capsule swallowing, gastric retention, and string retrieval will be evaluated using a Visual Analog Scale (VAS).

Potential procedure-related adverse events, including nausea, gagging, throat discomfort, mucosal irritation or injury, bleeding, and difficulty retrieving the string, will be monitored and documented. Clinically significant adverse events will be managed according to institutional clinical practice, and serious adverse events will be reported to the Institutional Review Board in accordance with applicable regulations.

Studietype

Ingrijpend

Inschrijving (Geschat)

40

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Taiwan
      • New Taipei City, Taiwan, Taiwan, 24352
        • Fu Jen Catholic University Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Yu-tse Chiu, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 75 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Adults aged 18-75 years.
  2. Completed a 13C-urea breath test (UBT) within 28 days prior to enrollment, with documented test results.
  3. Able to understand the study procedures and willing to provide written informed consent.

Exclusion Criteria:

  1. History of dysphagia, esophageal stricture, or gastrointestinal obstruction.
  2. Use of antibiotics, bismuth-containing agents, or proton pump inhibitors (PPIs) within 4 weeks prior to enrollment, as these medications may affect H. pylori antigen detection.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Diagnostisch
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: HP String Test With Rapid Antigen Assay

Gastric mucus collection using a minimally invasive string test followed by Helicobacter pylori rapid antigen testing. The investigational test results will be compared with the participants' existing ^13C-UBT results as the reference standard to evaluate diagnostic agreement and preliminary diagnostic accuracy.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Diagnostic Sensitivity and Specificity of the HP String Test With Rapid Antigen Assay
Tijdsspanne: At the study visit (approximately 1-2 hours after initiation of the string test procedure)

Diagnostic sensitivity and specificity of the gastric string test combined with a rapid antigen assay for detecting Helicobacter pylori infection, using the ^13C-urea breath test (UBT) as the reference standard (DOB ≥4.0 indicating a positive result and DOB <4.0 indicating a negative result).

At the study visit (approximately 1-2 hours after initiation of the string test procedure)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Correlation Between T-Line Color Intensity and ^13C-UBT DOB Values
Tijdsspanne: At the study visit (approximately 1-2 hours after initiation of the string test procedure)

The correlation between the test-line (T-line) color intensity of the gastric string test combined with a rapid antigen assay, graded on a standardized 0-4 ordinal scale, and the corresponding ^13C-urea breath test (UBT) delta-over-baseline (DOB) values will be assessed.

At the study visit (approximately 1-2 hours after initiation of the string test procedure)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

1 maart 2027

Studie voltooiing (Geschat)

1 maart 2027

Studieregistratiedata

Eerst ingediend

25 oktober 2026

Eerst ingediend dat voldeed aan de QC-criteria

25 oktober 2026

Eerst geplaatst (Werkelijk)

30 oktober 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

4 november 2026

Laatste update ingediend die voldeed aan QC-criteria

1 november 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Individual participant data (IPD) will not be shared with external researchers to protect participant confidentiality and comply with institutional data protection policies. Only aggregated study results and findings published in scientific journals will be made available.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren